The 3Rs-Centre Utrecht Life Sciences, Utrecht University, Utrecht, The Netherlands.
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
ALTEX. 2018;35(1):99-118. doi: 10.14573/altex.1705101. Epub 2017 Aug 9.
The supplementation of culture medium with fetal bovine serum (FBS, also referred to as "fetal calf serum") is still common practice in cell culture applications. Due to a number of disadvantages in terms of quality and reproducibility of in vitro data, animal welfare concerns, and in light of recent cases of fraudulent marketing, the search for alternatives and the development of serum-free medium formulations has gained global attention. Here, we report on the 3rd Workshop on FBS, Serum Alternatives and Serum-free Media, where regulatory aspects, the serum dilemma, alternatives to FBS, case-studies of serum-free in vitro applications, and the establishment of serum-free databases were discussed. The whole process of obtaining blood from a living calf fetus to using the FBS produced from it for scientific purposes is de facto not yet legally regulated despite the existing EU-Directive 2010/63/EU on the use of animals for scientific purposes. Together with the above-mentioned challenges, several strategies have been developed to reduce or replace FBS in cell culture media in terms of the 3Rs (Refinement, Reduction, Replacement). Most recently, releasates of activated human donor thrombocytes (human platelet lysates) have been shown to be one of the most promising serum alternatives when chemically-defined media are not yet an option. Additionally, new developments in cell-based assay techniques, advanced organ-on-chip and microphysiological systems are covered in this report. Chemically-defined serum-free media are shown to be the ultimate goal for the majority of culture systems, and examples are discussed.
在细胞培养应用中,添加胎牛血清(FBS,也称为“胎牛血清”)仍然是一种常见的做法。由于在体外数据的质量和重现性方面存在许多缺点、动物福利问题,以及最近出现的欺诈性营销案例,因此人们一直在寻找替代品,并开发无血清培养基配方,这引起了全球的关注。在这里,我们报告了第 3 届 FBS、替代血清和无血清培养基研讨会的情况,会上讨论了监管方面、血清困境、FBS 的替代品、无血清体外应用案例研究以及无血清数据库的建立。尽管存在关于科学目的使用动物的欧盟指令 2010/63/EU,但从活小牛胎儿中获取血液到使用由此产生的 FBS 用于科学目的的整个过程在事实上尚未受到法律监管。除了上述挑战外,还针对细胞培养培养基中的 FBS 提出了减少或替代的 3R(优化、减少、替代)策略。最近,激活的人类供体血小板(人血小板裂解物)的释放物已被证明是化学定义培养基不是一种选择时最有前途的血清替代品之一。此外,本报告还涵盖了基于细胞的测定技术、先进的器官芯片和微生理系统的新发展。化学定义的无血清培养基被证明是大多数培养系统的最终目标,并讨论了一些例子。